These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22998395)

  • 1. 'It looks like you just want them when things get rough': civil society perspectives on negative trial results and stakeholder engagement in HIV prevention trials.
    Koen J; Essack Z; Slack C; Lindegger G; Newman PA
    Dev World Bioeth; 2013 Dec; 13(3):138-48. PubMed ID: 22998395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Civil society perspectives on negative biomedical HIV prevention trial results and implications for future trials.
    Essack Z; Koen J; Slack C; Lindegger G; Newman PA
    AIDS Care; 2012; 24(10):1249-54. PubMed ID: 22360605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a Science of Community Stakeholder Engagement in Biomedical HIV Prevention Trials: An Embedded Four-Country Case Study.
    Newman PA; Rubincam C; Slack C; Essack Z; Chakrapani V; Chuang DM; Tepjan S; Shunmugam M; Roungprakhon S; Logie C; Koen J; Lindegger G
    PLoS One; 2015; 10(8):e0135937. PubMed ID: 26295159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convergent ethical issues in HIV/AIDS, tuberculosis and malaria vaccine trials in Africa: Report from the WHO/UNAIDS African AIDS Vaccine Programme's Ethics, Law and Human Rights Collaborating Centre consultation, 10-11 February 2009, Durban, South Africa.
    Mamotte N; Wassenaar D; Koen J; Essack Z
    BMC Med Ethics; 2010 Mar; 11():3. PubMed ID: 20211030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stakeholder perspectives on ethical challenges in HIV vaccine trials in South Africa.
    Essack Z; Koen J; Barsdorf N; Slack C; Quayle M; Milford C; Lindegger G; Ranchod C; Mukuka R
    Dev World Bioeth; 2010 Apr; 10(1):11-21. PubMed ID: 19459900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Civil society advocacy in Nigeria: promoting democratic norms or donor demands?
    Williamson RT; Rodd J
    BMC Int Health Hum Rights; 2016 Jul; 16(1):19. PubMed ID: 27400871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing community stakeholder engagement in biomedical HIV prevention trials: principles, practices and evidence.
    Newman PA; Rubincam C
    Expert Rev Vaccines; 2014 Dec; 13(12):1553-62. PubMed ID: 25174764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of national and international HIV/AIDS funding and governance mechanisms on the development of civil-society responses to HIV/AIDS in East and Southern Africa.
    Kelly KJ; Birdsall K
    AIDS Care; 2010; 22 Suppl 2():1580-7. PubMed ID: 21161762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Has global fund support for civil society advocacy in the former Soviet Union established meaningful engagement or 'a lot of jabber about nothing'?
    Harmer A; Spicer N; Aleshkina J; Bogdan D; Chkhatarashvili K; Murzalieva G; Rukhadze N; Samiev A; Walt G
    Health Policy Plan; 2013 May; 28(3):299-308. PubMed ID: 22767433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engaging diverse social and cultural worlds: perspectives on benefits in international clinical research from South african communities.
    Zvonareva O; Engel N; Ross E; Berghmans R; Dhai A; Krumeich A
    Dev World Bioeth; 2015 Apr; 15(1):8-17. PubMed ID: 23725088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A relative standard for minimal risk is unnecessary and potentially harmful to children: lessons from the Phambili trial.
    Nelson RM
    Am J Bioeth; 2011 Jun; 11(6):14-6. PubMed ID: 21678206
    [No Abstract]   [Full Text] [Related]  

  • 12. Circus monkeys or change agents? Civil society advocacy for HIV/AIDS in adverse policy environments.
    Spicer N; Harmer A; Aleshkina J; Bogdan D; Chkhatarashvili K; Murzalieva G; Rukhadze N; Samiev A; Walt G
    Soc Sci Med; 2011 Dec; 73(12):1748-55. PubMed ID: 22036298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A qualitative study of stakeholder and researcher perspectives of community engagement practices for HIV vaccine clinical trials in South Africa.
    Dietrich JJ; Munoz J; Tshabalala G; Makhale LM; Hornschuh S; Rentas F; Mulaudzi M; Laher F; Andrasik MP
    J Community Psychol; 2023 Apr; 51(3):998-1015. PubMed ID: 36342974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbicide research in developing countries: have we given the ethical concerns due consideration?
    Moodley K
    BMC Med Ethics; 2007 Sep; 8():10. PubMed ID: 17877834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Civil society organisations and global health initiatives: problems of legitimacy.
    Doyle C; Patel P
    Soc Sci Med; 2008 May; 66(9):1928-38. PubMed ID: 18291566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why we don't need a relative risk standard for adolescent HIV vaccine trials in South Africa.
    Slack CM
    Am J Bioeth; 2011 Jun; 11(6):21-2. PubMed ID: 21678209
    [No Abstract]   [Full Text] [Related]  

  • 17. Collateral benefits: how the practical application of Good Participatory Practice can strengthen HIV research in sub-Saharan Africa.
    Baron D; Essien T; Pato S; Magongo M; Mbandazayo N; Scorgie F; Rees H; Delany-Moretlwe S
    J Int AIDS Soc; 2018 Oct; 21 Suppl 7(Suppl Suppl 7):e25175. PubMed ID: 30334610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethics issues for HIV/AIDS researchers in international settings - perspectives from the Canadian experience.
    Gahagan J; Sweeney E; Worthington C; Perry D; Satzinger F; Rogers E
    Int J Infect Dis; 2008 Nov; 12(6):569-72. PubMed ID: 18829360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stakeholder views of ethical guidance regarding prevention and care in HIV vaccine trials.
    Moorhouse R; Slack C; Quayle M; Essack Z; Lindegger G
    BMC Med Ethics; 2014 Jun; 15():51. PubMed ID: 24981027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative versus absolute standards for everyday risk in adolescent HIV prevention trials: expanding the debate.
    Snyder J; Miller CL; Gray G
    Am J Bioeth; 2011 Jun; 11(6):5-13. PubMed ID: 21678205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.